The maximum time [h] to reach the equilibrium concentration for caprylate and NAT removal and adsorption capacity [mg/g] for caprylate and NAT of each adsorbent in the batch tests. de réir Stephan Harm (4794978)

Correlation of cigarette butts counted and removed in Round 1 with cigarette butts counted in Round 2. de réir Georg E. Matt (2098087)

Primers of this study. de réir Shuang Li (146392)

Ábhair:

Agarose gel electrophoresis results of PCR products. de réir Shuang Li (146392)

Ábhair:

The degradation of PNP by <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crc</i>Y, and DLL-Δ<i>crcZ</i>. de réir Shuang Li (146392)

Ábhair:

The growth of <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crcY</i>, and DLL-Δ<i>crcZ</i> on LB medium. de réir Shuang Li (146392)

Ábhair:

Aggregated results for reported benefits and harms, stratified by leaflets and booklets. de réir Maren Dreier (628959)

“…<p>The figure indicates whether a leaflet contains <u>any</u> information on the benefits of CRC screening a) in general or specifically for b) colonoscopy or c) the FOBT, and whether it contains any information on the d) general and e) specific harms of colonoscopy. To be rated positive for harms, it was not sufficient if the only information about possible harms referred to pain, stating incorrectly that there is no pain involved.…”

Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. de réir Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. de réir Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. de réir Diana M. Hendrickx (1507435)

Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. de réir Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. de réir Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. de réir Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. de réir Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. de réir Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... de réir Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. de réir Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. de réir Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... de réir Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using KEGG pathway enrichment in ConsensusPathDB. de réir Diana M. Hendrickx (1507435)